Morbidity and mortality in prostate cancer, the third most common cause of male cancer death in the United Kingdom (Waxman 1985) is generally related to the presence of bony metastases (VACURG 1976; Labasky & Smith 1988) which are identified in up to 84% of patients dying from the disease (Abrams et al., 1950) . Although such metastases are classically described as osteoblastic in character recent work has shown that abnormally high levels of bone resorption occur concurrently with new bone formation (Percival et al., 1987) . Histological studies confirm that increased erosion is present in both tumour free and infiltrated bone (Urwin et al., 1985) and that within resorption may be mediated both by increased osteoclast activity and the direct action of neoplastic cells (Galasko 1976) .
The bisphosphonate 3-Amino 1-Hydroxypropylidene-l, 1-Bisphosphonate (Pamidronate) is an inhibitor of osteoclast mediated osteolysis (Fleisch 1983) effective in the treatment of malignant hypercalcaemia (Sleeboom et al., 1983) . It has proved to be valuable in the palliative treatment of metastatic breast carcinoma, decreasing the overall incidence of morbidity ( Van-Holten Verzantvoort et al., 1987) and producing sclerosis in previously lytic deposits 
Results
Infusions were well tolerated and there were no significant side effects arising from the treatment. Four patients died during the 6 month study period and one was too ill to continue after 5 months therapy.
Pain and mobility Eight of 25 patients were pain free at entry: all remained pain free on treatment. Eleven of 17 patients with pain at the start of the trial had an improvement in their pain score with treatment. Six of 10 patients with mild to moderate pain became pain free by 3 months and none of these deteriorated thereafter. By 6 months three of these patients had died but pain was either better (two) or no worse (one) than at study entry. Seven patients had severe pain at the onset of treatment. One of these died with increased pain at 3 months whilst pain in five others improved by at least one grade with Pamidronate (additional local radiotherapy was required for one patient with persistent shoulder pain). Performance scores (Table I) broadly paralleled improvements in observed (Figure 2) showed that significant supression occurred after 3 months (P<0.0001) and was maintained thereafter. Alkaline phosphatase, initially raised in 18 patients (Figure 2 ) fell in 12 by 3 months, but at 6 months levels had begun to rise again in five. Eight further patients with normal levels at the outset (not illustrated) remained within the normal range throughout treatment. (Figure 3) . Levels continued to rise in the remaining five patients.
Discussion
Recognition that substantially increased bone resorption may occur in the presence of osteoblastic metastases has provided the rationale for the use of inhibitors of bone resorption in prostatic malignancy (Galasko 1976; Urwin et al., 1985; Percival et al., 1987) . Apart from two recent letters relating to Pamidronate therapy (Masud & Slevin 1989; Pelger et al., 1989) experience with bisphosphonates in prostate cancer has been limited to reports using earlier generation compounds; 1-Hydroxy Ethylidene-l 1-Bisphosphonate (Etidronate) diminished urinary OHP/Cr and CaE (Urwin et al., 1984) whilst Dichloromethylene Bisphosphonate (Clodronate), provided short term relief of bone pain (Adami et al., 1985) . In this preliminary study the efficacy of Pamidronate (which, unlike earlier bisphosphonates, will inhibit osteoclasts at doses with a minimal effect on bone mineralisation : Reitsma et al., 1983) has been examined in terms of subjective pain relief and objective measurable change in skeletal metabolic function. During the 6 month study period measurable improvements in pain and mobility were recorded. Although four patients died of advancing disease, in three of these bone pain remained well controlled and was not the predominant clinical problem during the terminal phase. Clearly, whilst these observations appear to suggest enhanced quality of life, the possible placebo effect of intensive support in the prostate cancer clinic and the subjective nature of pain relief demand that further controlled studies will be required to determine accurately the analgesic properties of this class of compound.
Although most patients demonstrated treatment-induced falls in urinary hydroxyproline levels (Figure la and lb) -a finding consistent with ongoing supression of pathological bone destruction -continuing elevation in others suggested a failure to reduce bone destruction. In such cases, the possibility that significant inhibition of the osteoclast resorption known to occur in the non-metastatic peripheral skeleton (Urwin et al., 1985) , is being masked by overwhelming direct tumour-driven bone destruction within the metastasis itself cannot be discounted. By contrast, fasting urinary CaE (Figure 1c) reduced in all cases regardless of the hydroxyproline excretion pattern. Serum osteocalcin also fell in all patients -albeit at a slower rate than urinary calcium excretionwhilst serum alkaline phosphatase demonstrated an inconsistent pattern. Dissociation in the levels of these two markers has been reported in Paget's disease of bone (Delmas et al., 1986 ) (a condition also associated with rapid bone formation) and probably reflects focal osteoblast dysfunction with impaired osteocalcin production in areas of high bone turnover. These observations illustrate that, whilst Pamidronate treatment exerts a significant and beneficial effect on bone metabolism in patients with prostate cancer, the complex changes occuring within the skeleton are unlikely to be explained by analysis of serum and urine data alone; direct histomorphometric measurements of metastatic and tumour free bone will be required to understand the precise mode of action of bisphosphonate therapy in this condition.
It was not surprising that, in contrast to recent studies in breast cancer 
